Preliminary results from a randomized, controlled, open-label, adaptive study on the use of dexamethasone were added to myMatrixx’s “Coronavirus Disease 2019 (COVID-19) – The Search for a Treatment” document. The recovery trial compared a ten day course of dexamethasone 6mg once per day versus standard hospital care for COVID-19 patients. Among the population receiving the drug, it was determined that it did reduce mortality in patients receiving machine-driven ventilated breathing by one third (29% versus 40.7%). While patients not on any breathing support saw no reduction in mortality. The authors concluded that patients who are suffering from severe respiratory complications due to COVID-19 would see a 28 day mortality reduction by up to 33% when treated with dexamethasone.
Download the latest version of our Issues Document below to learn more information regarding therapies in development for COVID-19.